Lupin Limited has informed the Exchange regarding a press release dated February 02, 2026, titled "Lupin Launches Dasatinib Tablets in the United States".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin Limited has launched Dasatinib Tablets in the US market, as announced via a press release dated February 02, 2026. Dasatinib is a generic oncology drug used in the treatment of chronic myeloid leukemia (CML). A US launch indicates that the product has received USFDA approval and is now commercially available in the world's largest generic pharmaceutical market. This adds to Lupin's existing US generics portfolio and supports growth in its largest overseas market.
Positive for shareholders — strengthens Lupin's US business and revenue base from the world's largest generics market. Likely to support steady US revenue growth, though generic pricing pressure may cap margin gains.